{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T06:14:48Z","timestamp":1777616088590,"version":"3.51.4"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T00:00:00Z","timestamp":1581379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T00:00:00Z","timestamp":1581379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Discov."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Regulated necrosis or necroptosis, mediated by receptor-interacting kinase 1 (RIPK1), RIPK3 and pseudokinase mixed lineage kinase domain-like protein (MLKL), contributes to the pathogenesis of inflammatory, infectious and degenerative diseases. Recently identified necroptosis inhibitors display moderate specificity, suboptimal pharmacokinetics, off-target effects and toxicity, preventing these molecules from reaching the clinic. Here, we developed a cell-based high-throughput screening (HTS) cascade for the identification of small-molecule inhibitors of necroptosis. From the initial library of over 250,000 compounds, the primary screening phase identified 356 compounds that strongly inhibited TNF-\u03b1-induced necroptosis, but not apoptosis, in human and murine cell systems, with EC<jats:sub>50<\/jats:sub>\u2009&lt;\u20096.7\u2009\u03bcM. From these, 251 compounds were tested for RIPK1 and\/or RIPK3 kinase inhibitory activity; some were active and several have novel mechanisms of action. Based on specific chemical descriptors, 110 compounds proceeded into the secondary screening cascade, which then identified seven compounds with maximum ability to reduce MLKL activation, IC<jats:sub>50<\/jats:sub>\u2009&gt;100\u2009\u03bcM, EC<jats:sub>50<\/jats:sub> 2.5\u201311.5\u2009\u03bcM under long-term necroptosis execution in murine fibroblast L929 cells, and full protection from ATP depletion and membrane leakage in human and murine cells. As a proof of concept, compound SN-6109, with binding mode to RIPK1 similar to that of necrostatin-1, confirmed RIPK1 inhibitory activity and appropriate pharmacokinetic properties. SN-6109 was further tested in mice, showing efficacy against TNF-\u03b1-induced systemic inflammatory response syndrome. In conclusion, a phenotypic-driven HTS cascade promptly identified robust necroptosis inhibitors with in vivo activity, currently undergoing further medicinal chemistry optimization. Notably, the novel hits highlight the opportunity to identify new molecular mechanisms of action in necroptosis.<\/jats:p>","DOI":"10.1038\/s41420-020-0240-0","type":"journal-article","created":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T17:16:06Z","timestamp":1581959766000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Phenotypic high-throughput screening platform identifies novel chemotypes for necroptosis inhibition"],"prefix":"10.1038","volume":"6","author":[{"given":"Hugo","family":"Brito","sequence":"first","affiliation":[]},{"given":"Vanda","family":"Marques","sequence":"additional","affiliation":[]},{"given":"Marta B.","family":"Afonso","sequence":"additional","affiliation":[]},{"given":"Dean G.","family":"Brown","sequence":"additional","affiliation":[]},{"given":"Ulf","family":"B\u00f6rjesson","sequence":"additional","affiliation":[]},{"given":"Nidhal","family":"Selmi","sequence":"additional","affiliation":[]},{"given":"David M.","family":"Smith","sequence":"additional","affiliation":[]},{"given":"Ieuan O.","family":"Roberts","sequence":"additional","affiliation":[]},{"given":"Martina","family":"Fitzek","sequence":"additional","affiliation":[]},{"given":"Nat\u00e1lia","family":"Aniceto","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5790-9181","authenticated-orcid":false,"given":"Rita C.","family":"Guedes","sequence":"additional","affiliation":[]},{"given":"Rui","family":"Moreira","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4829-754X","authenticated-orcid":false,"given":"Cec\u00edlia M. P.","family":"Rodrigues","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2020,2,11]]},"reference":[{"key":"240_CR1","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1111\/j.1582-4934.2007.00150.x","volume":"11","author":"RA Lockshin","year":"2007","unstructured":"Lockshin, R. A. & Zakeri, Z. Cell death in health and disease. J. Cell. Mol. Med 11, 1214\u20131224 (2007).","journal-title":"J. Cell. Mol. Med"},{"key":"240_CR2","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1080\/17474124.2017.1300060","volume":"11","author":"BL Woolbright","year":"2017","unstructured":"Woolbright, B. L., Ding, W. X. & Jaeschke, H. Caspase inhibitors for the treatment of liver disease: friend or foe? Expert Rev. Gastroenterol. Hepatol. 11, 397\u2013399 (2017).","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"240_CR3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1146\/annurev-pathol-052016-100247","volume":"12","author":"L Galluzzi","year":"2017","unstructured":"Galluzzi, L., Kepp, O., Chan, F. K.-M. & Kroemer, G. Necroptosis: mechanisms and relevance to disease. Annu. Rev. Pathol. Mech. Dis. 12, 103\u2013130 (2017).","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"240_CR4","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/nrd.2015.6","volume":"15","author":"M Conrad","year":"2016","unstructured":"Conrad, M., Angeli, J. P. F., Vandenabeele, P. & Stockwell, B. R. Regulated necrosis: Disease relevance and therapeutic opportunities. Nat. Rev. Drug Discov. 15, 348\u2013366 (2016).","journal-title":"Nat. Rev. Drug Discov."},{"key":"240_CR5","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","volume":"25","author":"L Galluzzi","year":"2018","unstructured":"Galluzzi, L. et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 25, 486\u2013541 (2018).","journal-title":"Cell Death Differ."},{"key":"240_CR6","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1111\/ajt.12448","volume":"13","author":"A Linkermann","year":"2013","unstructured":"Linkermann, A. et al. Necroptosis in immunity and ischemia-reperfusion injury. Am. J. Transpl. 13, 2797\u20132804 (2013).","journal-title":"Am. J. Transpl."},{"key":"240_CR7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41583-018-0093-1","volume":"20","author":"J Yuan","year":"2019","unstructured":"Yuan, J., Amin, P. & Ofengeim, D. Necroptosis and RIPK1-mediated neuroinflammation in CNS diseases. Nat. Rev. Neurosci. 20, 19\u201333 (2019).","journal-title":"Nat. Rev. Neurosci."},{"key":"240_CR8","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1080\/17460441.2018.1457644","volume":"13","author":"I Coornaert","year":"2018","unstructured":"Coornaert, I. et al. Novel drug discovery strategies for atherosclerosis that target necrosis and necroptosis. Expert Opin. Drug Discov. 13, 477\u2013488 (2018).","journal-title":"Expert Opin. Drug Discov."},{"key":"240_CR9","first-page":"215","volume":"40","author":"S Wang","year":"2016","unstructured":"Wang, S., Pacher, P., De Lisle, R. C., Huang, H. & Ding, W. X. A mechanistic review of cell death in alcohol-induced liver injury. Alcohol. Clin. Exp. Res. 40, 215\u20131223 (2016).","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"240_CR10","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s10495-015-1192-3","volume":"21","author":"G Wang","year":"2016","unstructured":"Wang, G., Qu, F. Z., Li, L., Lv, J. C. & Sun, B. Necroptosis: a potential, promising target and switch in acute pancreatitis. Apoptosis 21, 121\u2013129 (2016).","journal-title":"Apoptosis"},{"key":"240_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2016.280","volume":"7","author":"MB Afonso","year":"2016","unstructured":"Afonso, M. B. et al. Activation of necroptosis in human and experimental cholestasis. Cell Death Dis. 7, e2390 (2016).","journal-title":"Cell Death Dis."},{"key":"240_CR12","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nchembio711","volume":"1","author":"A Degterev","year":"2005","unstructured":"Degterev, A. et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat. Chem. Biol. 1, 112\u2013119 (2005).","journal-title":"Nat. Chem. Biol."},{"key":"240_CR13","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nchembio.83","volume":"4","author":"A Degterev","year":"2008","unstructured":"Degterev, A. et al. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat. Chem. Biol. 4, 313\u2013321 (2008).","journal-title":"Nat. Chem. Biol."},{"key":"240_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.298","volume":"8","author":"S Martens","year":"2017","unstructured":"Martens, S. et al. Sorafenib tosylate inhibits directly necrosome complex formation and protects in mouse models of inflammation and tissue injury. Cell Death Dis. 8, e2904 (2017).","journal-title":"Cell Death Dis."},{"key":"240_CR15","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1021\/acs.jmedchem.5b01898","volume":"59","author":"PA Harris","year":"2016","unstructured":"Harris, P. A. et al. DNA-encoded library screening identifies benzo[b][1,4]oxazepin-4-ones as highly potent and monoselective receptor interacting protein 1 kinase inhibitors. J. Med. Chem. 59, 2163\u20132178 (2016).","journal-title":"J. Med. Chem."},{"key":"240_CR16","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1080\/13543776.2016.1230201","volume":"26","author":"SR Kopalli","year":"2016","unstructured":"Kopalli, S. R., Kang, T. B. & Koppula, S. Necroptosis inhibitors as therapeutic targets in inflammation mediated disorders - a review of the current literature and patents. Expert Opin. Ther. Pat. 26, 1239\u20131256 (2016).","journal-title":"Expert Opin. Ther. Pat."},{"key":"240_CR17","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/nbt1186","volume":"24","author":"N Malo","year":"2006","unstructured":"Malo, N., Hanley, J. A., Cerquozzi, S., Pelletier, J. & Nadon, R. Statistical practice in high-throughput screening data analysis. Nat. Biotechnol. 24, 167\u2013175 (2006).","journal-title":"Nat. Biotechnol."},{"key":"240_CR18","unstructured":"Sittampalam, G. S. et al. Assay Guidance Manual. (Eli Lilly & Company and the National Center for Advancing Translational Sciences: Bethesda (MD), 2004."},{"key":"240_CR19","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1128\/AAC.01640-12","volume":"57","author":"AC Jacobs","year":"2013","unstructured":"Jacobs, A. C. et al. Adenylate kinase release as a high-throughput-screening-compatible reporter of bacterial lysis for identification of antibacterial agents. Antimicrob. Agents Chemother. 57, 26\u201336 (2013).","journal-title":"Antimicrob. Agents Chemother."},{"key":"240_CR20","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/icb.2016.118","volume":"95","author":"L Vasilikos","year":"2017","unstructured":"Vasilikos, L., Spilgies, L. M., Knop, J. & Wong, W. W. L. Regulating the balance between necroptosis, apoptosis and inflammation by inhibitors of apoptosis proteins. Immunol. Cell Biol. 95, 160\u2013165 (2017).","journal-title":"Immunol. Cell Biol."},{"key":"240_CR21","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.molcel.2014.10.021","volume":"56","author":"P Mandal","year":"2014","unstructured":"Mandal, P. et al. RIP3 induces apoptosis independent of pronecrotic kinase activity. Mol. Cell 56, 481\u2013495 (2014).","journal-title":"Mol. Cell"},{"key":"240_CR22","doi-asserted-by":"publisher","first-page":"309","DOI":"10.18632\/oncotarget.1480","volume":"5","author":"C Billard","year":"2014","unstructured":"Billard, C. Apoptosis inducers in chronic lymphocytic leukemia. Oncotarget 5, 309\u2013325 (2014).","journal-title":"Oncotarget"},{"key":"240_CR23","doi-asserted-by":"crossref","unstructured":"Fauster, A. et al. A cellular screen identifies ponatinib and pazopanib as inhibitors of necroptosis. Cell Death Dis. 6, e1767 (2015).","DOI":"10.1038\/cddis.2015.130"},{"key":"240_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.241","volume":"5","author":"JX Li","year":"2014","unstructured":"Li, J. X. et al. The B-Raf V600E inhibitor dabrafenib selectively inhibits RIP3 and alleviates acetaminophen-induced liver injury. Cell Death Dis. 5, e1278 (2014).","journal-title":"Cell Death Dis."},{"key":"240_CR25","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1021\/acs.jmedchem.7b01449","volume":"61","author":"S Hofmans","year":"2018","unstructured":"Hofmans, S. et al. Tozasertib analogues as inhibitors of necroptotic cell death. J. Med. Chem. 61, 1895\u20131920 (2018).","journal-title":"J. Med. Chem."},{"key":"240_CR26","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/med.10041","volume":"23","author":"I Muegge","year":"2003","unstructured":"Muegge, I. Selection criteria for drug-like compounds. Med. Res. Rev. 23, 302\u2013321 (2003).","journal-title":"Med. Res. Rev."},{"key":"240_CR27","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.cell.2011.11.031","volume":"148","author":"L Sun","year":"2012","unstructured":"Sun, L. et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell 148, 213\u2013227 (2012).","journal-title":"Cell"},{"key":"240_CR28","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.cbpa.2010.03.020","volume":"14","author":"N Thorne","year":"2010","unstructured":"Thorne, N., Auld, D. S. & Inglese, J. Apparent activity in high-throughput screening: origins of compound-dependent assay interference. Curr. Opin. Chem. Biol. 14, 315\u2013324 (2010).","journal-title":"Curr. Opin. Chem. Biol."},{"key":"240_CR29","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.4161\/cbt.21115","volume":"13","author":"B Tang","year":"2012","unstructured":"Tang, B., Testa, J. R. & Kruger, W. D. Increasing the therapeutic index of 5-fluorouracil and 6-thioguanine by targeting loss of MTAP in tumor cells. Cancer Biol. Ther. 13, 1082\u20131090 (2012).","journal-title":"Cancer Biol. Ther."},{"key":"240_CR30","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.cell.2009.05.021","volume":"137","author":"S He","year":"2009","unstructured":"He, S. et al. Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-\u03b1. Cell 137, 1100\u20131111 (2009).","journal-title":"Cell"},{"key":"240_CR31","doi-asserted-by":"publisher","first-page":"W443","DOI":"10.1093\/nar\/gkv315","volume":"43","author":"S Salentin","year":"2015","unstructured":"Salentin, S., Schreiber, S., Haupt, V. J., Adasme, M. F. & Schroeder, M. PLIP: fully automated protein-ligand interaction profiler. Nucleic Acids Res. 43, W443\u2013W447 (2015).","journal-title":"Nucleic Acids Res."},{"key":"240_CR32","doi-asserted-by":"crossref","unstructured":"Oliveira, S. R. et al. Phenotypic screening identifies a new oxazolone inhibitor of necroptosis and neuroinflammation. Cell Death Discov. 5, 65 (2018).","DOI":"10.26226\/morressier.5b31ec2d2afeeb001345a566"},{"key":"240_CR33","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1126\/science.3764421","volume":"234","author":"KJ Tracey","year":"1986","unstructured":"Tracey, K. J. et al. Shock and tissue injury induced by recombinant human cachectin. Science 234, 470\u2013474 (1986).","journal-title":"Science"},{"key":"240_CR34","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.immuni.2011.09.020","volume":"35","author":"L Duprez","year":"2011","unstructured":"Duprez, L. et al. RIP kinase-dependent necrosis drives lethal systemic inflammatory response syndrome. Immunity 35, 908\u2013918 (2011).","journal-title":"Immunity"},{"key":"240_CR35","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.4155\/fmc.11.149","volume":"3","author":"DA Volpe","year":"2011","unstructured":"Volpe, D. A. Drug-permeability and transporter assays in Caco-2 and MDCK cell lines. Future Med. Chem. 3, 2063\u20132077 (2011).","journal-title":"Future Med. Chem."},{"key":"240_CR36","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1084\/jem.165.3.657","volume":"165","author":"V Lehmann","year":"1987","unstructured":"Lehmann, V., Freudenberg, M. A. & Galanos, C. Lethal toxicity of lipopolysaccharide and tumor necrosis factor in normal and D-galactosamine-treated mice. J. Exp. Med 165, 657\u2013663 (1987).","journal-title":"J. Exp. Med"},{"key":"240_CR37","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.chembiol.2015.11.008","volume":"23","author":"BK Wagner","year":"2016","unstructured":"Wagner, B. K. & Schreiber, S. L. The power of sophisticated phenotypic screening and modern mechanism-of-action methods. Cell Chem. Biol. 23, 3\u20139 (2016).","journal-title":"Cell Chem. Biol."},{"key":"240_CR38","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1084\/jem.187.9.1477","volume":"187","author":"D Vercammen","year":"1998","unstructured":"Vercammen, D. et al. Inhibition of caspases increases the sensitivity of L929 cells to necrosis mediated by tumor necrosis factor. J. Exp. Med. 187, 1477\u20131485 (1998).","journal-title":"J. Exp. Med."},{"key":"240_CR39","doi-asserted-by":"publisher","first-page":"6465","DOI":"10.1016\/j.febslet.2005.10.041","volume":"579","author":"CP Lawrence","year":"2005","unstructured":"Lawrence, C. P. & Chow, S. C. FADD deficiency sensitises Jurkat T cells to TNF-\u03b1-dependent necrosis during activation-induced cell death. FEBS Lett. 579, 6465\u20136472 (2005).","journal-title":"FEBS Lett."},{"key":"240_CR40","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1164\/rccm.201510-2106CI","volume":"194","author":"G Moreno-Gonzalez","year":"2016","unstructured":"Moreno-Gonzalez, G., Vandenabeele, P. & Krysko, D. V. Necroptosis: A novel cell death modality and its potential relevance for critical care medicine. Am. J. Respir. Crit. Care Med. 194, 415\u2013428 (2016).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"240_CR41","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/nature14191","volume":"517","author":"M Pasparakis","year":"2015","unstructured":"Pasparakis, M. & Vandenabeele, P. Necroptosis and its role in inflammation. Nature 517, 311\u2013320 (2015).","journal-title":"Nature"},{"key":"240_CR42","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/nrm.2016.149","volume":"18","author":"R Weinlich","year":"2017","unstructured":"Weinlich, R., Oberst, A., Beere, H. M. & Green, D. R. Necroptosis in development, inflammation and disease. Nat. Rev. Mol. Cell Biol. 18, 127\u2013136 (2017).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"240_CR43","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1007\/s11064-017-2249-1","volume":"42","author":"L Shao","year":"2017","unstructured":"Shao, L., Yu, S., Ji, W., Li, H. & Gao, Y. The contribution of necroptosis in neurodegenerative diseases. Neurochem. Res. 42, 2117\u20132126 (2017).","journal-title":"Neurochem. Res."},{"key":"240_CR44","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.semcdb.2014.07.013","volume":"35","author":"W Zhou","year":"2014","unstructured":"Zhou, W. & Yuan, J. Necroptosis in health and diseases. Semin. Cell Dev. Biol. 35, 14\u201323 (2014).","journal-title":"Semin. Cell Dev. Biol."},{"key":"240_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.316","volume":"6","author":"H Zhao","year":"2015","unstructured":"Zhao, H. et al. Role of necroptosis in the pathogenesis of solid organ injury. Cell Death Dis. 6, e1975 (2015).","journal-title":"Cell Death Dis."},{"key":"240_CR46","doi-asserted-by":"publisher","first-page":"117967071769125","DOI":"10.1177\/1179670717691251","volume":"10","author":"B M\u00e9ry","year":"2017","unstructured":"M\u00e9ry, B. et al. In Vitro cell death determination for drug discovery: a landscape review of real issues. J. Cell Death 10, 1179670717691251 (2017).","journal-title":"J. Cell Death"},{"key":"240_CR47","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1016\/j.cell.2016.11.047","volume":"167","author":"J Yuan","year":"2016","unstructured":"Yuan, J., Najafov, A. & Py, B. F. Roles of caspases in necrotic cell death. Cell 167, 1693\u20131704 (2016).","journal-title":"Cell"},{"key":"240_CR48","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/cdd.2015.70","volume":"23","author":"DA Rodriguez","year":"2016","unstructured":"Rodriguez, D. A. et al. Characterization of RIPK3-mediated phosphorylation of the activation loop of MLKL during necroptosis. Cell Death Differ. 23, 76\u201388 (2016).","journal-title":"Cell Death Differ."},{"key":"240_CR49","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1089\/sur.2016.021","volume":"17","author":"AJ Lewis","year":"2016","unstructured":"Lewis, A. J., Seymour, C. W. & Rosengart, M. R. Current murine models of sepsis. Surg. Infect. 17, 385\u2013393 (2016).","journal-title":"Surg. Infect."},{"key":"240_CR50","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1111\/j.1476-5381.2010.01127.x","volume":"162","author":"JP Hughes","year":"2011","unstructured":"Hughes, J. P., Rees, S. S., Kalindjian, S. B. & Philpott, K. L. Principles of early drug discovery. Br. J. Pharm. 162, 1239\u20131249 (2011).","journal-title":"Br. J. Pharm."},{"key":"240_CR51","doi-asserted-by":"publisher","first-page":"8994","DOI":"10.1074\/jbc.RA118.002776","volume":"293","author":"JY Tretter","year":"2018","unstructured":"Tretter, J. Y. et al. A high-content screen for small-molecule regulators of epithelial cell-adhesion molecule (EpCAM) cleavage yields a robust inhibitor. J. Biol. Chem. 293, 8994\u20139005 (2018).","journal-title":"J. Biol. Chem."},{"key":"240_CR52","doi-asserted-by":"publisher","first-page":"429","DOI":"10.2165\/00003088-198106060-00002","volume":"6","author":"NHG Holford","year":"1981","unstructured":"Holford, N. H. G. & Sheiner, L. B. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin. Pharmacokinet. 6, 429\u2013453 (1981).","journal-title":"Clin. Pharmacokinet."},{"key":"240_CR53","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.pharmthera.2012.01.001","volume":"134","author":"A Astashkina","year":"2012","unstructured":"Astashkina, A., Mann, B. & Grainger, D. W. A critical evaluation of in vitro cell culture models for high-throughput drug screening and toxicity. Pharmacol. Ther. 134, 82\u2013106 (2012).","journal-title":"Pharmacol. Ther."},{"key":"240_CR54","doi-asserted-by":"publisher","first-page":"16065","DOI":"10.1038\/cddiscovery.2016.65","volume":"2","author":"C-Y Lin","year":"2016","unstructured":"Lin, C.-Y. et al. Simultaneous induction of apoptosis and necroptosis by Tanshinone IIA in human hepatocellular carcinoma HepG2 cells. Cell Death Discov. 2, 16065 (2016).","journal-title":"Cell Death Discov."},{"key":"240_CR55","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.bbrc.2013.01.126","volume":"432","author":"H Sawai","year":"2013","unstructured":"Sawai, H. Differential effects of caspase inhibitors on TNF-induced necroptosis. Biochem. Biophys. Res. Commun. 432, 451\u2013455 (2013).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"240_CR56","doi-asserted-by":"publisher","first-page":"4231","DOI":"10.2174\/092986710793348545","volume":"17","author":"R Sink","year":"2010","unstructured":"Sink, R., Gobec, S., Pecar, S. & Zega, A. False positives in the early stages of drug discovery. Curr. Med. Chem. 17, 4231\u20134255 (2010).","journal-title":"Curr. Med. Chem."},{"key":"240_CR57","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1021\/jm5019093","volume":"58","author":"JL Dahlin","year":"2015","unstructured":"Dahlin, J. L. et al. PAINS in the assay: chemical mechanisms of assay interference and promiscuous enzymatic inhibition observed during a sulfhydryl-scavenging HTS. J. Med. Chem. 58, 2091\u20132113 (2015).","journal-title":"J. Med. Chem."},{"key":"240_CR58","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.4155\/fmc.14.72","volume":"6","author":"JWM Nissink","year":"2014","unstructured":"Nissink, J. W. M. & Blackburn, S. Quantification of frequent-hitter behavior based on historical high-throughput screening data. Future Med. Chem. 6, 1113\u20131126 (2014).","journal-title":"Future Med. Chem."},{"issue":"Suppl 3","key":"240_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2202-9-S3-S7","volume":"9","author":"FF Hefti","year":"2008","unstructured":"Hefti, F. F. Requirements for a lead compound to become a clinical candidate. BMC Neurosci. 9(Suppl 3), S7 (2008).","journal-title":"BMC Neurosci."}],"container-title":["Cell Death Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41420-020-0240-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-020-0240-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-020-0240-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T16:16:51Z","timestamp":1670257011000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41420-020-0240-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,11]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["240"],"URL":"https:\/\/doi.org\/10.1038\/s41420-020-0240-0","relation":{},"ISSN":["2058-7716"],"issn-type":[{"value":"2058-7716","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,11]]},"assertion":[{"value":"21 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.G.B., U.B., N.S., D.M.S., I.O.R. and M.F. are employees and share holders of AstraZeneca. Other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"6"}}